Questions week 13

1. How the expression of RAS-G12D is activated in these transgenic animals?

(it is not part of the cancer lecture, but this is a general mechanism discussed in molecular biology class to regulate gene expression in transgenic animal models.. to refresh your memory)

2. Which are the normal cells that originate lung cancer in these mice?

3. What is the stroma in the tissue organization?

4. Is myc directly altering the stroma composition?

5. What is the difference between tissue-resident macrophages and circulating macrophages?

6. CCL9 is synthesized in the cytoplasm and released extracellularly. The blocking antibodies are blocking the activity of CCL9 cytoplasmatic or extracellular?

7. What does VEFG stand for?

8. How would you define the lung cancer tumor derived from ras-myc activation as immune desert, excluded, or inflamed?

9. If a Myc inhibitor is available what will happen to these tumors?

Groups for discussion

Figure 1
Figure 2 a-b
Figure 2c
Figure 3
Figure 4a-d
Figure 4e-f
Figure 5